Treatment resistant schizophrenia (TRS) has a severe clinical and economic impact on patients, carers, families and society as the whole. Research on TRS has generated several hypotheses to explain the underlying pathophysiology. This video provides an overview of one such hypothesis.
Related content
Professor Dr. Merete Nordentoft introduces her work with the population of children of parents with schizophrenia. She also highlights the model implemented in Denmark, called VIA family, and why it is important to focus on children of parents living with schizophrenia.
Professor Dr. Christoph Correll highlights the recent innovations in the pharmacological treatment of schizophrenia.
Dr. Marco Solmi introduces what the mortality gap is and why there is a mortality gap in schizophrenia.